Publicaciones en colaboración con investigadores/as de Ikerbasque, Fundación Vasca para la Ciencia (59)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  3. Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression

    Hepatology, Vol. 77, Núm. 5, pp. 1654-1669

  4. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  5. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma

    Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108

2022

  1. Application of adipose-derived mesenchymal stem cells in an in vivo model of peripheral nerve damage

    Frontiers in Cellular Neuroscience, Vol. 16

  2. Bona fide atypical scrapie faithfully reproduced for the first time in a rodent model

    Acta Neuropathologica Communications, Vol. 10, Núm. 1

  3. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121

  4. Identification and Functional Analysis of a Novel CTNNB1 Mutation in Pediatric Medulloblastoma

    Cancers, Vol. 14, Núm. 2

  5. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734

  6. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  7. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation

    Journal of Hepatology, Vol. 77, Núm. 4, pp. 991-1004

  8. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190

  9. The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes

    Nature Communications, Vol. 13, Núm. 1

2021

  1. Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity

    Cell Death and Disease, Vol. 12, Núm. 6

  2. Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury

    JHEP Reports, Vol. 3, Núm. 3

  3. Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)

    British Journal of Cancer

  4. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  5. Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System

    Hepatology, Vol. 73, Núm. 6, pp. 2311-2325

  6. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477